|
1.
|
|
8 p, 500.4 KB |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
/
Siena, S (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Sartore-Bianchi, A (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Garcia-Carbonero, R (Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO, CIBERONC, Universidad Complutense, Madrid, Spain) ;
Karthaus, M (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ;
Smith, D (Department of Gastroenterology, University Hospital of Bordeaux, Hopital Haut Levaeque, Bordeaux, France) ;
Tabernero, J (Universitat Autònoma de Barcelona) ;
Van Cutsem, E (KU Leuven, Leuven, Belgium) ;
Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ;
Boedigheimer, M (Amgen Inc., Thousand Oaks, CA, USA) ;
Ang, A (Amgen Inc., Thousand Oaks, CA, USA) ;
Twomey, B (Amgen Inc., Thousand Oaks, CA, USA) ;
Bach, B A (Amgen Inc., Thousand Oaks, CA, USA) ;
Jung, A S (Amgen Inc., Thousand Oaks, CA, USA) ;
Bardelli, A (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 -  10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126
|
|
|
2.
|
|
7 p, 740.6 KB |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
/
Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ;
Felip Font, Enriqueta (Universitat Autònoma de Barcelona) ;
Matito, J (Institut d'Oncologia de la Vall d'Hebron) ;
Mereu, Elisabetta (Universitat Pompeu Fabra) ;
Navarro, A (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, S (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Núria (Universitat Autònoma de Barcelona) ;
Martinez de Castro, A (Vall d'Hebron Institut d'Oncologia) ;
Remon, J (Vall d'Hebron Institut d'Oncologia) ;
Miquel, J M (Vall d'Hebron Institut d'Oncologia) ;
Guillaumet-Adkins, A (Universitat Pompeu Fabra) ;
Nadal, E (Institut Català d'Oncologia) ;
Rodriguez Esteban, Gustavo (Universitat Pompeu Fabra) ;
Arqués, O (Stem Cells and Cancer Group) ;
Fasani, R (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ;
Palmer, H G (Stem Cells and Cancer Group) ;
Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. [...]
2017 - 10.1093/annonc/mdx396
Annals of oncology, Vol. 28 (july 2017) , p. 2451-2457
|
|
|
3.
|
|
7 p, 176.2 KB |
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review
/
García-Foncillas, J (Hospital Universitario Fundación Jiménez Díaz) ;
Alba, E (Hospital Universitario Regional Virgen de la Victoria, IBIMA, Málaga) ;
Aranda, E (Hospital Reina Sofía, Cordoba) ;
Díaz Rubio, E (Universidad Complutense de Madrid. Hospital Clínico San Carlos) ;
López López, R (Hospital Clínico Universitario (Santiago de Compostela)) ;
Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ;
Vivancos, A (Vall d'Hebron Institut d'Oncologia)
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. [...]
2017 - 10.1093/annonc/mdx501
Annals of oncology, Vol. 28 (september 2017) , p. 2943-2949
|
|
|
4.
|
|
9 p, 341.6 KB |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
/
Conteduca, V. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wetterskog, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Sharabiani (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ;
Grande, E. (Hospital Ramon y Cajal. Departamento de Oncologia Médica) ;
Fernandez Perez, M. P. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ;
Jayaram, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Castellano, D. (Hospital Universitario 12 de Octubre. Departamento de Oncologia Médica) ;
Romanel, A. (Università di Trento. Centro di Biologia Integrata) ;
Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Casadio, V. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gurioli, G. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Font, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vazquez Estevez, S. (, Hospital Universitario Lucus Augusti. Departamento de Oncologia Médica) ;
González del Alba, A. (Hospital Universitario Son Espases Mallorca. Departament d'Oncologia Médica) ;
Mellado, B. (IDIBAPS Hospital Clinic. Departament d'Oncologia Médica) ;
Fernandez Calvo, O. (Hospital de Ourense. Departamento de Oncologia Médica) ;
Méndez Vidal, M. J. (Hospital Universitario Reina Sofía. Departamento de Oncologia Médica) ;
Climent, M. A. (Instituto Valenciano de Oncología) ;
Duran, I. (Instituto de Biomedicina de Sevilla) ;
Gallardo, E. (Hospital Universitari Parc Taulí. Departament d'Oncologia Médica) ;
Rodriguez, A. (Hospital de León. Departamento de Oncologia Médica) ;
Santander, C. (Hospital Universitario Miguel Servet. Departamento de Oncologia Médica) ;
Sáez, M. I. (Hospital Regional y Hospital Virgen de la Victoria, Malaga. Departamento de Oncologia Médica) ;
Puente, J. (Hospital Clínico San Carlos. Departamento de Oncologia Médica) ;
Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wingate, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Dearnaley, D. (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ;
Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ;
De Giorgi, U. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gonzalez Billalabeitia, E. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ;
Attard, G. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Spanish Oncology Genitourinary Group ;
Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of Oncology, Núm. 28 (2017) , p. 1508-1516
|
|
|
5.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, S. (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y.H. (Experimental Therapeutics Group) ;
Gris-Oliver, A. (Experimental Therapeutics Group) ;
Bonache, S. (Oncogenetics Group) ;
Morancho, B. (Vall d'Hebron Institut d'Oncologia) ;
Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U.M. (Cancer Research UK. Cambridge Institute) ;
Jones, G.N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzman, M. (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, J. (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratú, G. (Cancer Genomics Group) ;
Mancuso, F. (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W.J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital de la Vall d'Hebron) ;
Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J.C. (AstraZeneca (USA)) ;
Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ;
Baselga Torres, Josep, 1959-, (Memorial Sloan Kettering Cancer Center (USA)) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Jonkers, J. (Cancer Genomics Group) ;
Díez, Orland (Hospital Vall d'Hebron) ;
O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
|
6.
|
|
11 p, 388.8 KB |
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
/
Arnold, D (Instituto CUF de Oncologia (I.C.O.), Lisboa) ;
Fuchs, C S (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ;
Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ;
Ohtsu, A (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Zhu, A X (Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA) ;
Garon, E B (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ;
Mackey, J R (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ;
Paz Ares, L (Hospital Universitario Doce de Octubre. Departamento de Oncologia Médica) ;
Baron, A D (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ;
Okusaka, T (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ;
Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Yoon, H H (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ;
Das, M (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, D (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Binder, P (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Sashegyi, A (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Chau, I (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942
|
|
|
7.
|
|
7 p, 242.6 KB |
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies
/
Boeckx, N. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ;
Koukakis, R. (Biostatistics, Amgen Ltd) ;
Op de Beeck, K. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ;
Rolfo, C. (Department of Oncology, Antwerp University Hospital, Edegem) ;
Van Camp, G. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ;
Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ;
Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Douillard, J.-Y. (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ;
André, T. (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ;
Peeters, M. (Department of Oncology, Antwerp University Hospital, Edegem)
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868
|
|
|
8.
|
|
8 p, 357.7 KB |
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
/
Grasselli, J (Institut Català d'Oncologia) ;
Élez Fernández, Mª Elena (Universitat Autònoma de Barcelona) ;
Caratù, G (Vall d'Hebron Institut d'Oncologia) ;
Matito, J (Vall d'Hebron Institut d'Oncologia) ;
Santos, C (Institut Català d'Oncologia) ;
Macarulla Mercadé, Teresa (Universitat Autònoma de Barcelona. Hospital Universitari de la Vall d'Hebron) ;
Vidal, J (Hospital del Mar. Departament d'Oncologia) ;
Garcia, M (Institut Català d'Oncologia) ;
Viéitez, J M (Hospital Universitario de Asturias. Departamento de Oncologia Médica) ;
Paéz, D (Institut d'Investigació Biomèdica Sant Pau) ;
Falcó, E (Hospital Universitari Son Llatzer. Departament d'Oncologia Mèdica) ;
Lopez Lopez, C (Hospital Universitario Marqués de Valdecilla. Departamento de Oncología Médica) ;
Aranda, E (Hospital Universitario Reina Sofía (Córdoba). Departamento de Oncología Médica) ;
Jones, F (Sysmex Inostics, Mundelein, USA) ;
Sikri, V (Sysmex Inostics, Mundelein, USA) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Fasani, R (Vall d'Hebron Institut d'Oncologia) ;
Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ;
Montagut, C (Hospital del Mar. Departament d'Oncologia) ;
Azuara, D (Institut Català d'Oncologia) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Salazar, R (Institut Català d'Oncologia) ;
Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301
|
|
|
9.
|
|
8 p, 412.5 KB |
Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
/
Obermannová, R. (Masaryk Memorial Cancer Institute (Czech Republic)) ;
Van Cutsem, E. (KU Leuven. University Hospitals Leuven (Belgium)) ;
Yoshino, T. (National Cancer Center Hospital East (Japan)) ;
Bodoky, G. (St László Hospital (Hungary)) ;
Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ;
Garcia-Carbonero, R. (Hospital Universitario Doce de Octubre) ;
Ciuleanu, T. (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ;
Garcia Alfonso, P. (Hospital General Universitario Gregorio Maraňón) ;
Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ;
Cohn, A. (Rocky Mountain Cancer Center (USA)) ;
Yamazaki, K. (Shizouka Cancer Center (Japan)) ;
Clingan, P. (Southern Medical Day Care Centre (Australia)) ;
Lonardi, S. (Istituto Oncologico Veneto-IRCCS (Italy)) ;
Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ;
Yang, L. (Eli Lilly and Company (USA)) ;
Nasroulah, F. (Eli Lilly and Company (República Argentina)) ;
Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ;
Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090
|
|
|
10.
|
|
7 p, 199.8 KB |
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
/
Chiorean, E. G. (University of Washington. Department of Medicine) ;
Von Hoff, D. D. (Translational Genomics Research Institute) ;
Reni, M. (Ospedale San Raffaele. Servizio di Oncologia Medica) ;
Arena, F. P. (NYU Langone Arena Oncology. Department of Oncology) ;
Infante, J. R. (Sarah Cannon Research Institute) ;
Bathini, V. G. (University of Massachusetts Medical School. Cancer Center of Excellence) ;
Wood, T. E. (University of Alabama at Birmingham. Comprehensive Cancer Center) ;
Mainwaring, P. N. (Centre for Haematology & Oncology (Brisbane, Austràlia)) ;
Muldoon, R. T. (Genesis Cancer Center. Department of Oncology) ;
Clingan, P. R. (Southern Medical Day Care Centre) ;
Kunzmann, V. (Universitätsklinikum Würzburg. Medizinischen Klinik und Poliklinik II) ;
Ramanathan, R. K. (Translational Genomics Research Institute) ;
Tabernero Caturla, Josep (Hospital Universitari de la Vall d'Hebron) ;
Goldstein, D. (Prince of Wales Hospital. Department of Oncology) ;
McGovern, D. (Celgene Corporation) ;
Lu, B. (Celgene Corporation) ;
Ko, A. (Celgene Corporation) ;
Universitat Autònoma de Barcelona
Any CA19-9 decline at week 8 and radiologic response by week 8 each predicted longer OS in both treatment arms. In the nab- P + Gem arm, the higher proportion of patients with week 8 CA19-9 decrease [82% (206/252); median OS 13. [...]
2016 - 10.1093/annonc/mdw006
Annals of oncology, Vol. 27, issue 4 (April 2016) , p. 654-660
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
